18th Annual International Lung Cancer Congress®
Past Events

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 22.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 22.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grants from AbbVie, AstraZeneca, BeyondSpring Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Lilly, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

18th Annual International Lung Cancer Congress®

July 27 - 29, 2017
Hyatt Regency Huntington Beach
21500 Pacific Coast Highway
Huntington Beach, CA
Reservation: (888) 421-1442


The 18th Annual International Lung Cancer Congress® will provide current, practical information on the management of lung cancer, as well as a look at the novel agents and strategies with the potential to shape the future of lung cancer therapy. Leading international and national experts will address critical topics in lung cancer screening, personalized therapy, and the latest clinical data impacting the treatment of lung cancer. Cutting-edge lectures, panel discussions, multidisciplinary tumor boards, and interactive question-and-answer sessions will provide a unique opportunity for participants to engage with faculty as they share their perspectives and personal experiences on the clinical challenges and ongoing controversies in lung cancer management. The meeting will continue the tradition of highlighting the clinical research activity of Cooperative Groups in the United States, Europe, and Asia.

Target Audience

This educational activity is directed toward medical, surgical and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers and other healthcare professionals interested in the treatment of lung cancer are also invited to attend.

Learning Objectices

  • Delineate testing strategies for the diagnosis and identification of biomarkers which can be used to facilitate clinical decision-making in multiple lines of lung cancer care
  • Explain evolving treatment strategies for early-stage and locally advanced lung cancer
  • Determine optimized sequencing strategies for the management of advanced lung cancer based on clinical data sets, performance status, and tumor characteristics
  • Assess current data sets and ongoing clinical trials evaluating single agent and combination immunotherapeutic approaches
  • Place recent clinical trial results on chemotherapeutic, targeted, and immunotherapeutic strategies in the context of current treatment standards and evolving paradigms in the management of lung cancer
  • Explain the current status of cooperative group trials and methods to facilitate participation in clinical trials that are assessing emerging strategies to treat lung cancer

Program Directors

David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT

Calendar of Events
Filter By